Abstract
Dementia associated with high numbers of neuritic plaques and neurofibrillary tangles, detected post-mortem, are the defining features of Alzheimer’s disease. In addition, there is region-specific loss of neuronal populations. There is general cortical shrinkage as well as regional and cell-specific degeneration and loss of neurons. The temporal lobe seems to be more affected than other cortical areas. There is degeneration of neuronal populations providing ascending afferents to hippocampal and cortical structures. Such changes are most prominent in the cholinergic basalo-cortical and noradrenergic coeruleo-cortical systems. NGF has been proposed as therapeutic treatment for Alzheimer’s disease, based on the loss of cholinergic neurons and the pronounced trophic action of NGF on these cells. There is a decrease of cholinergic function in hippocampus and cortex illustrated by a loss of presynaptic cholinergic markers, ChAT activity, high-affinity choline uptake, the number of nicotinic receptors (Bowen et al., 1976; Davies and Maloney, 1976; Araujo et al., 1988) and a loss of cholinergic cell bodies in basal forebrain which provide the innervation of cortex and hippocampus (Whitehouse et al., 1982). These cells express rather selectively the NGF receptor proteins, gp145trk A and p75LNGFR. In animals, experimental lesions of the cholinergic neurons innervating hippocampus and cortex result in pronounced deficits in memory and cognitive functions which can be reversed by administration of drugs enhancing cholinergic function (Murray and Fibiger, 1985; Ridley et al., 1986; Tilson et al., 1988; Miyamoto et al., 1989). Enhancement of cholinergic function by drugs (e.g., acetylcholinesterase inhibitors) in Alzheimer patients produce modest, but significant ameliorations (Mohs et al., 1985; Thal et al., 1986; Eagger et al., 1991; Davis et al., 1992; Farlow et al., 1992).
Keywords
- Nerve Growth Factor
- Cholinergic Neuron
- Basal Forebrain
- Nerve Growth Factor Receptor
- Cholinergic Function
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Araujo, D.M., Lapchak, P.A., Robitaille, Y., Gauthier, S., and Quirion, R., 1988, Differential alteration of various cholinergic markers in cortical and sub-cortical regions of the human brain in Alzheimer’s disease, J. Neurochem. 50: 1914.
Bowen, D.M., Smith, C.B., White, P., and Davison, A.N., 1976, Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies, Brain 99: 459.
Clatterbuck, R.E., Price, D.L., and Koliatsos, V.E., 1993, Ciliary neurotropic factor prevents retrograde neuronal death in the adult central nervous system, Proc. Natl. Acad. Sci. 90: 2222.
Crutcher, K.A., Scott, S.A., Liang, S., Everson, W.V., and Weingartner, J., 1993, Detection of NGF-like activity in human brain tissue, increased levels in Alzheimer’s disease, J. Neurosci. 13: 2540.
Cummings, B.J., Yee, G.J., and Colman, C.W., 1992, bFGF promotes the survival of entorhinal layer II neurons after perforant path axotomy, Brain Res. 591: 271.
Davies, P., and Maloney, A.J.F., 1976, Selective loss of central cholinergic neurons in Alzheimer’s disease, Lancet 11: 1403.
Davis, K.L., Thal, L.J., Gamzu, E R, Davis, C.S., Woolson, R.F., Gracon, S.I., Drachman, D.A., Schneider, L.S., Whitehouse P.J., Hoover, T.M., Morris, J.C., Kawas, C.H., Knopman, D.S., Earl, N.L., Kumar, V., Doody, R.S., and Tacrine Collaborative Study Group, 1992, A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer’s disses, New Engl. J. Med. 327: 1253.
Dekker, A.J., Langdon, D.J., Gage, F.H., and Thal, L.J., 1991, NGF increases cortical acetylcholine release in rats with lesions of the nucleus basalis, NeuroReport 2: 577.
Dekker, A.J., Gage, F.H., and Thal, L.J., 1992, Delayed treatment with nerve growth factor improves acquisition of a spatial task in rats with lesions of the nucleus basalis magnocellularis: evaluation of the involvement of different neurotransmitter systems, Neuroscience 48: 111.
Eagger, S.A., Levy, R., and Sahakian, B.J., 1991, Tacrine in Alzheimer’s disease, Lancet 337: 989
Emfors, P., Ibanez, C.F., Ebendal, T., Olson, L., and Persson, H., 1990, Molecular cloning and neurotrophic activities of a protein with structural similarities to nerve growth factor: developmental and topographic expression in the brain, Proc. Natl. Acad. Sci. USA 87: 5454.
Farlow, M., Gracon, S.I., Hershey, L.A., Lewis, K.W., Sadowski, C.H., and Dolan-Ureno, J., 1992, A controlled trial of tacrine in Alzheimer’s disease, JAMA 268: 2523.
Fischer, W., Wictorin, K., Bjorklund, A., Williams, L.R., Varon, S., and Gage, F.H., 1987, Amelioration of cholinergic neurons atrophy and spatial memory impairment in aged rats by nerve growth factor, Nature 329: 65.
Friedman, W.J., Ibanez, C.F., Hallbook, F., Persson, H., Cain, L.D., Dreyfus, C.F., and Black, I.B., 1993, Differential actions of neurotrophins in the locus coeruleus and basal forebrain, Exp. Neurol. 119: 72.
Goedert, M., Fine, A., Dawbarn, D., Wilcock, G.K., and Chao, M.V., 1989, Nerve growth factor receptor mRNA distribution in human brain: normal levels in basal forebrain in Alzheimer’s disease, Mol. Brain Res. 5: 1.
Hefti, F., 1986, Nerve growth factor (NGF) promotes survival of septal cholinergic neurons after fimbrial transections, J. Neurosci. 6: 2155.
Hefti, F., and Mash, D.C., 1989, Localization of nerve growth factor receptors in the normal human brain and in Alzheimer’s disease, Neurobiol. Aging 10: 75.
Hefti, F., David, A., and J. Hartikka., 1984, Chronic intraventricular injections of nerve growth factor elevate hippocampal choline acetyltransferase activity in adult rats with partial septo-hippocampal lesions, Brain Res. 293.
Higgins, G.A., and Mufson, E.J., 1989, NGF receptor gene expression is decreased in the nucleus basalis in Alzheimer’s disease, Exp. Neurol. 106: 222.
Isaacson, L.G., Saffran, B.N., and K.A. Crutcher, 1990, Intracerebral NGF Infusion Induces Hyperinnervation of Cerebral Blood Vessels, in: “Neurobiology of Aging, ”Pergamon Press, 11: 51.
Junard, E.O., Montero, C.N., and F. Hefti., 1990, Long-term administration of mouse nerve growth factor to adult rats with partial lesions of the cholinergic septohippocampal pathway, Exp. Neurol. 110: 25.
Koliatsos, V.E., Applegate, M.D., Knusel, B., Burton, L.E., Mobley, W.C., Hefti, F., and Price, D.L., 1991, Recombinant human nerve growth factor prevents retrograde degeneration of axotomized basal forebrain cholinergic neurons in the rat, Exp. Neurol. 112: 161.
Lapchak, P.A., and Hefti, F., 1991, Effect of recombinant human nerve growth factor on presynaptic cholinergic function in rat hippocampal slices following partial septo-hippocampal lesions: measures of ACh synthesis, ACh release and choline acetyltransferase activity, Neuroscience 42: 639.
Lapchak, P.A., Jenden, D.J., and Hefti, F., 1992, Pharmacological stimulation reveals recombinant human nerve growth factor-induced increases of in vivo hippocampal cholinergic function measured in rats with partial fimbrial transections, Neuroscience 50: 847.
Loy, R., Heyer, D., Clagett-Dame, M., and DiStefano, P.S., 1990, Localization of NGF receptors in normal and Alzheimer’s basal forebrain with mondonal antibodies against the truncated form of the receptor, J. Neurosci. Res. 27: 651.
Mandel, R.J., Gage, F.H., and Thal, L.J., 1989, Spatial learning in rats: correlation with cortical choline acetyltransferase and improvement with NGF following NBM damage, Exp. Neurol. 104: 208.
Miyamoto, M., Narumi, S., Nagaoka, A., and Coyle, J.T., 1989, Effects of continuous infusion of cholinergic drugs on memory impairment in rats with basal forebrain lesions, J. Pharmacol. Exp. Ther. 248: 825.
Mobley, W.C., Neve, R.L., Prusiner, S.B., and McKinley, M.P., 1988, Nerve growth factor induces gene expression for prion-and Alzheimer’s beta-amyloid proteins, Proc. Natl. Acad. Sci. USA 85: 9811.
Mohs, R.C., Davis, B.M., Johns, C.A., Mathé, A.A., Greenwald, B.S., Horvath, T.B., and Davis, K.L., 1985, Oral physostigmine treatment of patients with Alzheimer’s disease. Amer. J. Psychiatr. 142: 28.
Murase, K., Nabeshima, T., Robitaille, Y., Quirion, R., Ogawa, M., and Hayashi, K., 1993, NGF level is not decreased in the serum, brain-spinal fluid, hippocampus, or parietal cortex of individuals with Alzheimer’s disease, Biochem. Biophys. Res. Commun. 193: 198.
Murray, C.L., and Fibiger, H.C., 1985, Learning and memory deficits after lesions of the nucleus basalis magnocellularis: Reversal by physostigmine, Neuroscience 14: 1025.
Olson, L., Nordberg, A., von Holst, H., Backman, L., Ebendahl, T., Alafuzoff, I., Amberla, K., Hartvig, P., Herlitz, A., Lilja, A. Lundquist, H. Langstron, B., Meyerson, B., Persson, A., Viitanen, M., Winblad, B., and Seiger, A., 1992, Nerve growth factor affects 11C-nicotine binding, blood flow, EEG and verbal episodic memory in an Alzheimer patient, J. Neurol. Transm. [P-D Sect] 4: 79.
Phelps, C.H., Gage, F.H., Growdon, J.H., Hefti, F., Harbaugh, R., Johnston, M.V., Khachaturian, Z.S., Mobley, W.C., Price, D.L., Raskind, M., Simpkins, J., Thal, L.J., and Woodcock, J., 1989
Potential use of nerve growth factor to treat Alzheimer’s disease, Neurobiol. Aging 10:205.
Phillips, H.S., Hains, J.M., Armanini, M., Laramee, G.R., Johnson, S.A., and Winslow, J.W., 1991, BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer’s disease, Neuron 7: 695.
Ridley, R.M., Murray, T.K., Johnson, J.A., and Baker H.F., 1986, Learning impairment following lesion of the basal nucleus of Meynert in the marmoset: Modification by cholinergic drugs, Brain Res. 376: 108.
Thal, L.J., Masur, D.M., Sharpless, N.S., Fuld, P.A., and Davies, P., 1986, Acute and chronic effects of oral physostigmine and lecithin in Alzheimer’s disease, Prog. Neuropsychopharmacol. Biol. Psychiatry 10: 617.
Tilson, H.A., McLamb, R.L., Shaw, S., Rogers, B.C., Pediaditakis, P., and Cook, L., 1988, Radial-maze deficits produced by colchicine administered into the area of the nucleus basalis are ameliorated by cholinergic agents, Brain Res. 438: 83.
Treanor, J.J.S., Dawbarn, D., Allen, S.J., MacGowan, S.H., and Wilcock, G.K., 1991, Low affinity nerve growth factor receptor binding in normal and Alzheimer’s disease basal forebrain, Neurosci. Lett. 121: 73.
Tuszynski, M.H., U, H.S., Yoshida, K., and Gage, F.H., 1991, Recombinant human nerve growth factor infusions prevent cholinergic neuronal degeneration in the adult primate brain, Ann. Neurol. 30: 625.
Whitehouse, P.J., Price, D.L., Struble, R.G., Clark, A.W., Coyle, J.T., and M.R. De Long., 1982, Alzheimer’s dis a»n and senile dementia; loss of neurons in the basal forebrain, Science 215: 1237.
Will, B., and F. Hefti., 1985, Behavioral and neurochemical effects of chronic intraventricular injections of nerve growth factor in adult rats with fimbria lesions, Behay. Brain Res. 17: 17.
Williams, L.R., 1990, Exogenous nerve growth factor stimulates choline acetyltransferase activity in aging Fisher 344 male rats, Neurobiol. Aging 12: 39.
Williams, L.R., 1991, Hypophagia is induced by intracerebroventricular administration of nerve growth factor, Exp. Neurol. 113: 31.
Williams, L.R., Varon, S., Peterson, G.M., Wictorin, K., Fischer, W., Bjorklund, A., and Gage, F.H., 1986, Continuous infusion of nerve growth factor prevents basal forebrain neuronal death after fimbria fornix transection, Proc. Natl. Acad. Sci. USA 83: 9231.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer Science+Business Media New York
About this chapter
Cite this chapter
Hefti, F. (1995). Neurotrophic Factor Therapy of Alzheimer’s Disease. In: Hanin, I., Yoshida, M., Fisher, A. (eds) Alzheimer’s and Parkinson’s Diseases. Advances in Behavioral Biology, vol 44. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-9145-7_87
Download citation
DOI: https://doi.org/10.1007/978-1-4757-9145-7_87
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-9147-1
Online ISBN: 978-1-4757-9145-7
eBook Packages: Springer Book Archive